Zheng Quan Ri Bao·2025-07-25 11:12Group 1 - The World Health Organization (WHO) reports that 119 countries and regions have identified the spread of Chikungunya virus, with approximately 5.5 million people at risk, potentially leading to widespread outbreaks that could strain health systems [1] - Several A-share listed companies have made strategic moves in response to the Chikungunya virus, including Ayhuilong, Shuoshi Biology, Aotai Biology, Rendu Biology, and Rainbow Group, who have shared their plans on the stock exchange interaction platform [1] Group 2 - Chikungunya fever is primarily transmitted by Aedes mosquitoes, with symptoms including fever, rash, and joint pain. Measures such as eliminating breeding sites and insect extermination can help interrupt transmission [2] - The Guangdong Province reported a local outbreak of Chikungunya fever linked to imported cases, with 3,645 confirmed cases reported as of July 23, all mild, and 2,018 patients have recovered [2] - The National Disease Control Bureau and the Guangdong Provincial Health Commission have dispatched expert teams to guide and participate in epidemic prevention efforts, focusing on cutting community transmission and preventing the spread of the outbreak [2] Group 3 - Multiple A-share listed companies are developing testing solutions for Chikungunya virus, primarily for research purposes or overseas markets. Ayhuilong's partner company has developed a rapid screening kit, while Shuoshi Biology and Aotai Biology also have testing kits available for research use [3] - Currently, there are no approved Chikungunya testing kits in the domestic market, but the approval process for related testing products is expected to accelerate [3] - Rainbow Group offers a wide range of household insecticide products aimed at mosquito control, including electric mosquito repellent and aerosol insecticides, which utilize high-quality active ingredients recommended by WHO [3]